SYSTEMATIC REVIEWS AND META-ANALYSES

ENERgized vessel sealing systems versus CONventional hemostasis techniques in thyroid surgery—the ENERCON systematic review and network meta-analysis

Pietro Contin • Käthe Gooßen • Kathrin Grummich • Katrin Jensen • Hubertus Schmitz-Winnenthal • Markus W. Büchler • Markus K. Diener

Received: 4 July 2013 / Accepted: 25 October 2013 / Published online: 16 November 2013 © Springer-Verlag Berlin Heidelberg 2013

Abstract

Purpose Energized vessel-sealing systems have been proposed to save operation time and reduce post-operative complications. The aim of the present systematic review was to compare operation time and postoperative morbidity for ultrasonic and electrothermal bipolar-activated devices with conventional hemostasis techniques and with each other in open thyroidectomy.

Methods A systematic literature search (MEDLINE, Cochrane Library, EMBASE and ISI Web of Science) was performed to identify randomised controlled trials (RCTs) comparing conventional hemostasis techniques, ultrasonic devices (Harmonic[®] scalpel) and/or electrothermal bipolaractivated vessel sealing systems (Ligasure[®]) during open thyroidectomy. For the primary endpoint (operation time), a network meta-analysis with Bayesian random effects model was performed. Pairwise meta-analyses with random effects were calculated for primary and secondary endpoints.

Electronic supplementary material The online version of this article (doi:10.1007/s00423-013-1137-7) contains supplementary material, which is available to authorized users.

P. Contin · H. Schmitz-Winnenthal · M. W. Büchler · M. K. Diener (☑)
Department of General-, Visceral- and Transplantation Surgery, University of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
e-mail: markus.diener@med.uni-heidelberg.de

P. Contin · K. Gooßen · K. Grummich · M. W. Büchler · M. K. Diener Study Centre of the German Surgical Society, University of Heidelberg, Heidelberg, Germany

K. Jensen

Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany

Results One hundred sixteen publications were evaluated for eligibility; 35 RCTs (4,061 patients) were included. There was considerable methodological and clinical heterogeneity of included trials. The Harmonic scalpel significantly reduced operation time compared with conventional techniques (22.26 min, 22.7 min in the inconsistency model). The use of Ligasure significantly reduced operation time in total thyroidectomy (13.84 min in the consistency model, 12.18 min in the inconsistency model). In direct comparison, operations with the Harmonic scalpel were faster than with Ligasure (8.42 min in the consistency model, 2.45 min in the inconsistency model). The rates of recurrent nerve palsy and postoperative hypocalcaemia did not significantly differ in the intervention groups.

Conclusions This meta-analysis shows superiority of ultrasonic devices in terms of operation time compared with conventional hemostasis techniques in thyroid surgery, with no detriment to safety outcomes.

Keywords Thyroid surgery · Hemostasis · Energized vessel sealing · Clamp and tie · Bipolar devices · Ultrasonic devices

Introduction

Surgery is the standard therapy for many thyroid diseases. Resections of the thyroidal gland are frequently performed in general surgery. In the United States, the surgical volume reaches 80,000 thyroidectomies per year [1].

Due to the high vascularisation of the thyroid gland, hemostasis is one of the keys limiting morbidity and mortality in thyroid surgery. Besides bleeding, major potential sources of postoperative morbidity following thyroid resections are dysphonia and dysphagia owing to unilateral—or bilateral—recurrent and/or superior laryngeal nerve injury, hypocalcaemia due to parathyroid ischemia or unintended deprivation, postsurgical haemorrhage and neck hematoma [2, 3]. Other less frequent surgical complications include wound infection, postoperative pain due to brachial plexus stretching and unsatisfactory cosmetic results [4]. The risk of perioperative mortality or major disability after surgery is low: The peri-operative mortality and haemorrhage are <1 % and about 1 %, respectively, and the nerve palsy rates range between 2 and 6 % [5].

Although minimally invasive or video-assisted surgery is employed increasingly, the open surgical approach is still the standard of care. In recent years, new energised vessel sealing systems such as electrothermal bipolar-activated devices (e.g. LigaSure[®], LS) or ultrasonic systems (e.g. UltraCision[®] or Harmonic Focus® devices, HS) have been applied to thyroid surgery with the aim of reducing blood loss, operating time and length of skin incision. The LS creates a seal using a combination of pressure and electrothermal energy to change the vessel wall structure and obliterate the lumen. A characteristic specific to the LS is the possibility to modulate the quantity of energy by applying appropriate pressure to the grip [6]. The HS uses mechanical energy (ultrasound) to simultaneously cut and seal vessels by denaturing and coagulating collagen fibres. Both types of devices have been tested in a number of randomised controlled trials (RCTs) since 2000.

Most of these individual RCTs were powered to detect a decrease in operation time as the primary endpoint. A metaanalysis will allow to better quantify the magnitude of the effect on operation time and to compare all three techniques with each other. Moreover, it may provide sufficient statistical power for detecting differences in safety outcomes. Although several reviews exist evaluating the potential superiority of energized devices in thyroid surgery [7–13], they each have limitations (e.g. regarding comparisons made and completeness of evidence that made an updated systematic review of the literature desirable).

The aim of the ENERCON systematic review and metaanalysis was to conduct a three-way comparison between energised vessel sealing systems (HS and LS) and conventional "clamp-and-tie" or traditional electrosurgical methods to evaluate operation time and post-operative complications in thyroid surgery.

Methods

This systematic review and meta-analysis was performed in accordance with the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" statement [14].

Search strategy

A systematic literature search was conducted independently by three authors (P.C., K.Go. and K.Gr.) according to the standards of the Cochrane collaboration. The following databases were searched: MEDLINE (via PubMed), Cochrane Library, EMBASE and ISI Web of Science. No language or time-period restrictions were applied. For MEDLINE, the Cochrane highly sensitive search strategy for RCTs was employed [15]. The search was carried out on 25 July 2012. An update on 12 December 2012 yielded no new studies. Other sources searched for relevant trials are reference lists of previous systematic reviews and included trials, journal homepages and publications citing included trials. Experts in the field of thyroid surgery were contacted to ensure that all relevant studies were included. The detailed search strategy used in MEDLINE is presented in Table 1.

Eligibility criteria

Publications related to the trials that met the following criteria were eligible for inclusion. RCTs without any language restriction comparing at least two of the following hemostasis techniques in open partial and/or total thyroidectomy: ultrasonic systems (UltraCision®, Harmonic Ace®, Harmonic Focus® or related systems, HS), electrothermal bipolar-activated vessel sealing systems (LigaSure® Precise, LF1212 or unspecified LigaSure instruments, LS) or conventional techniques for hemostasis (CH). Conventional hemostasis was defined as knotting and tying the vessels, applying vascular clips or using traditional electrosurgery. Trials evaluating methods for minimally invasive or video-assisted surgery were excluded. Eligibility was assessed for each publication by two authors (out of P.C., K.Go. and K.Gr.). Any disagreement was resolved by discussion.

Data Extraction

Data were extracted using a standardised electronic extraction sheet (available upon request).

The primary outcome parameter was total operation time, defined as the time from skin incision to skin closure. Secondary outcome parameters were as follows: postoperative mortality, intraoperative blood loss, weight of specimen, length of hospital stay, transitory and definitive laryngeal palsy (within or over 30 days after operation as has been used in most of the included articles), transient and persistent hypocalcaemia (within or over 90 days after operation), amount of drainage fluid (millilitres) 24 h after operation, rates of: hematoma/seroma (combined), reoperations and wound infections, as well as postoperative pain after 24 h (visual analogue scale) and any information on the cosmetic result.

The following baseline characteristics were recorded: study name, publication year, journal reference, country, funding, study design (number of participating centres, treatment arms, study duration, randomization, allocation concealment,

Table 1 Search strategy in MEDLINE

Population	(((Thyroid) AND (surgery OR operation OR resection OR lobectomy)) OR (thyroidectomy OR thyroidectomies OR hemithyroidectomy OR hemithyroidectomies) OR thyroidectomy[MeSH Terms]) AND
Interventions/control	(((Vessel OR vascular) AND (sealing OR occlusion)) OR (hemostasis OR haemostasis OR devascularization OR diathermy OR "bleeding control") OR (Hemostatic Techniques [MeSH Terms]))
	AND
	((Conventional OR traditional OR monopolar OR ligation OR tying OR tie OR ties OR clamp OR clamps OR clamping OR clip OR clips OR knot OR knots) OR (sutureless OR device OR devices OR coagulator OR coagulation OR energized OR energised OR bipolar OR electrocoagulation OR electrothermal OR electrosealing OR ligasure OR thermostapler OR harmonic OR ultrasonic OR focus OR ultracision)) AND
Outcomes	Outcomes were not used as a search criterion
Study types (Cochrane highly sensitive search strategy for RCTs)	(((Randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomized[tiab]) OR (placebo[tiab]) OR (drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR(groups[tiab])) NOT (animals[mh] NOT humans[mh]))

blinding), participants (main inclusion and exclusion criteria, sample size; baseline data such as age, gender, body mass index, American Society of Anaesthesiologists (ASA) classification, thyroid function, type of thyroid disease, concomitant treatment with non-steroidal anti-inflammatory drugs or anticoagulants), interventions (intervention groups, type of surgery, surgical experience). In case of missing data regarding the primary outcome, corresponding authors were contacted via mail by P.C. and K.G. to gather further information.

If a study generated multiple publications, data were extracted from the most comprehensive. Additional publications were used to complete this information.

Quality assessment

The methodological quality of the included studies was assessed using the Cochrane Risk of Bias tool [16]. Random sequence generation was considered adequate if the allocation process was determined by a chance process and unpredictable (e.g. drawing techniques, random-number tables or computerised random number generation). Allocation concealment was judged to be satisfactory whenever clinicians and participants were unaware of upcoming assignments (e.g. centralised allocation, sealed envelopes). Recognising the difficulties of blinding the surgical team, performance bias was considered low if patients were blinded to the treatment arm. Most outcomes were considered objective, not requiring blinding of outcome assessment to avoid detection bias. Detection bias was considered low in subjective outcomes (pain, cosmetic satisfaction) if assessors were blinded to the treatment arm. Analyses were considered adequate if all recruited patients were analysed in the group to which they were originally allocated, regardless of the treatment received (intention-to-treat principle (ITT)). Outcome data were considered complete (low attrition bias) if analysis was performed according to the ITT principle or if there were explicitly no withdrawals or patients lost to follow-up. Selective reporting was assessed by comparison of reported endpoints with abstracts and previously published study protocols and by whether variance measures were reported for each outcome. Other important sources of bias considered were the role of funding and the relative experience of the operating surgeons in each group.

Statistical analysis

For the primary endpoint "total operation time," we used a Bayesian random effects model for multiple treatment comparison with minimally informative prior distributions. It preserves the comparison of randomised treatments within each trial while combining all available comparisons between treatments and accounts for multiple comparisons within a trial when there are more than two treatment arms [17]. The model included random effects at the level of trials to account for variation between trials due to clinical heterogeneity. Whenever possible, we used results of intention-to-treat analysis including all randomised patients. Pooled effect sizes were estimated from the mean or the median, as specified, of the posterior distribution. A positive effect size of one treatment versus another indicates a benefit in operation time of the latter treatment. The 95 % credible intervals were estimated from the 2.5th and 97.5th centiles of the posterior distribution. Credible intervals in Bayesian statistics can be interpreted in a similar way to conventional confidence intervals in frequentist statistics.

In the multiple treatment comparison model, heterogeneity was estimated from the median standard deviation between trials (τ) observed in the posterior distribution with a uniform distribution (τ unif(0,5)) as prior distribution. For all trial baselines and treatment effects, vague priors (normal (0, 10, 000)) were used. The total residual deviance and the deviance information criterion (DIC) were given as goodness-of-fit measures. The consistency assumption was tested by the method of Bucher et al. [18] comparing the effect size from direct comparisons within randomised trials and the effect size from indirect comparisons between randomised trials with one intervention in common. All Bayesian analyses are based on 150,000 iterations, of which the first 50,000 were discarded as burn-in period. Convergence of Markov chains was checked by the Brooks–Gelman–Rubin statistic.

Finally, we performed pairwise meta-analyses with random effects at the level of trials for primary and secondary endpoints. Each pairwise meta-analytical comparison was restricted to the corresponding trial results irrespective of whether a third treatment arm was investigated. For the primary endpoint, subgroup analyses by sort of thyroidectomy (total, partial or total, partial), by sponsor (industry-sponsored, investigator-initiated, unclear sponsor) and by surgical experience (balanced, high risk for unbalance, unclear experience) were added.

For continuous endpoints, the effect size per trial was calculated by the mean difference (MD) between treatment groups and pooled as the weighted mean difference (WMD) with 95 % confidence interval using the inverse variance method. If in case of continuous data, estimates for mean and standard deviations (SD) were not reported, we used the methods by Hozo et al. [19] to convert median and range estimates into mean and SD. For dichotomous secondary endpoints, the risk difference (RD) was chosen as effect size measure per trial due to sparse data and pooled by the Mantel-Haenszel method [15]. All results were investigated for clinical and statistical heterogeneity. Clinical heterogeneity was explained where appropriate and possible. Statistical heterogeneity was explored by I^2 statistic.

We used WinBUGS (Version 1.4, MRC Biostatistics Unit 2003, Cambridge, UK) for multiple treatment comparisons and RevMan (Version 5.1, Nordic Cochrane Centre 2011, Cochrane Collaboration, Copenhagen) for pairwise meta-analyses.

Results

The electronic and manual literature searches identified 116 potentially eligible titles and abstracts. The study flow and reasons for exclusion are detailed in Fig. 1. Overall, 39 publications with the results of 35 trials were included in the qualitative and quantitative data synthesis.

The clinical characteristics of included trials are presented in Table 2. All were published between 2000 and 2012. One multicenter trial was retrieved [42], and in two cases, a university centre with satellite hospital was involved [30, 51]. Trials were performed worldwide, with an emphasis on Italy (14 trials). The majority of publications were in English, four in Italian [27, 33, 49, 55], and one each in German [50] and French [21]

Out of 4,061 randomized patients, the percentage of females ranged from 59 to 94 % and the mean age from 40 to 56 years (Table 3). Fifteen trials were limited to patients with benign disease; eighteen trials included patients with both benign and malignant thyroid diseases, and two trials included only patients with papillary carcinoma. Twenty trials dealt only with total thyroidectomies, and in three trials, this was combined with central neck or lymph node dissection (CND). Exclusively, partial thyroidectomies were performed in one trial. In the remaining 11 trials, both total and partial thyroidectomies were performed. Information on body mass index, ASA status, thyroid function and use of non-steroidal anti-inflammatory drugs and anticoagulants was not provided to a sufficient extent for further data analysis.

Risk of bias

The quality of included studies varied in terms of sample size, allocation concealment and blinding as well as of other sources of bias (Fig. 2, Electronic supplementary material Figure 1 and Electronic supplementary material Table 1). Overall, the quality of reporting was low, with the majority of studies revealing few methodological details.

Less than a third reported adequate methods of allocation concealment. Blinding of participants was not stated in 26/35 trials; the remainder reported patient blinding. In only one study [37], the observer was also blinded for outcome assessment. The risk of detection bias was considered low for endpoints other than pain scores and cosmetic satisfaction because of their objectivity.

Surgical experience was described in the majority of studies (27/35, 77 %). In 21 studies, a limited number of experienced surgeons performed all procedures, so that bias from this source is likely to be low. Junior surgeons participated in six trials. In two of these [20, 50], randomisation was stratified by surgical experience, and the resulting intervention groups were balanced with respect to senior and junior surgeons. In the other four, risk of bias is high because the junior surgeons may have tended to perform the conventional procedure more often. Finally, no information on surgical experience was provided in eight trials. The influence of both funding source and surgical experience on the primary outcome was investigated in subgroup analyses as detailed below.

Primary outcome: operation time

Operation time was generally defined as the time from first skin incision to skin closure.

Fig. 1 Number of abstracts and

articles identified and evaluated



Network meta-analysis for primary outcome

Out of 35 trials, 34 trials were included in the networkanalysis for the primary endpoint. Marchesi [24] had to be excluded because of a dichotomisation of operation time. Three trials had a three-arm parallel group design (CH vs. HS vs. LS, 303 patients), the remainder a two-arm parallel group design (21 trials: CH vs. HS, 2,371 patients; 7 trials: CH vs. LS, 730 patients; 3 trials: HS vs. LS, 471 patients) (Fig. 3).

The results of the multiple treatment comparison are presented in Table 4. Heterogeneity between trials was high in relation to the mean treatment effects (τ =4.91 between-trial standard deviation in the consistency model, τ =4.87 in the inconsistency model). In other words, most of the study effects (95%) ranges twice the between-trial standard deviation, here around ± 9.8 min, in both directions from each estimated treatment effect given in Table 4. The Bucher test for inconsistency revealed a significant difference between the direct comparison HS vs. LS and indirect comparison HS vs. LS derived from the comparisons CH vs. HS and CH vs. LS (p =0.013). In consequence, the results of a consistency model [59] as well as an inconsistency model [60] are given. In contrast to the consistency model, the inconsistency model takes a possible discrepancy between the direct and the indirect estimated treatment effect of HS vs. LS statistically into account.

The mean treatment effect of CH versus HS and CH versus LS of both models were concordant with a reduction in operation time of around 22 min under HS or of around 13 min under LS in comparison to CH, respectively (CH versus HS—22.26 with 95 % credible interval 19.87 to 24.65 in the consistency model, 22.7 with 95 % credible interval 20.23 to 25.17 in the inconsistency model; CH versus

LS—13.84 with 95 % credible interval 10.27 to 17.39 in the consistency model, 12.18 with 95 % credible interval 8.029 to 16.32 in the inconsistency model).

The mean treatment effect of HS versus LS differed substantially between the two models. In mean, a thyroidectomy under HS took around 8 min less than under LS, according to the consistency model and around only 2 min less according to the inconsistency model (HS versus LS, -8.42 with 95 % credible interval -12.14 to -4.73 in the consistency model, -2.45 with 95 % credible interval -9.484 to 4.595 in the inconsistency model). The total residual deviance and the DIC as measures of model fit gave no hint of which model is more appropriate.

Pairwise meta-analysis for primary outcome

Comparison of CH with HS

All trials comparing CH with HS (2,573 patients) demonstrated a significant reduction of operation time with HS. The pooled estimate was 23.6 min (95 % CI, [19.5, 27.6]; P <0.001; 24 studies, I^2 =89 %; Fig. 4) in correspondence with the results of the network meta-analysis. The mean difference between the treatment arms ranged from 6.7 to 47.3 min throughout studies.

In subgroup analyses for total thyroidectomies, the mean reduction of operation time was 24.9 min (95 % CI, [19.9, 29.9]; 20 trials, $I^2=91$ %), in trials with partial or total thyroidectomies 18.6 min (95 % CI, [9.8, 27.4]; 4 trials, $I^2=67$ %) and in partial thyroidectomies 17.4 min (95 % CI, [14.1, 20.7]; 3 trials, $I^2=0$ %). A sensitivity analysis excluding three-arm studies provided similar results.

A subgroup analysis by sponsor revealed that industrysponsored trials had a significantly lower mean difference in

Table 2 Clinical chi	aracteristic	cs of included t	rials						
Study	Ref.	Recruitment	Country	Intervention	Instrument	Control	Surgical experience	Primary endpoint	Power analysis
HS vs. conventional									
Voutilainen 2000	[20]	1997–1999	Finland	SH	UltraCision scalpel	CH	SS+JS (consultants+senior residents)	Operation time	Yes
Meurisse 2000	[21–23]	Unclear	Belgium	HS	UltraCision HS002	CH	UN	Not clearly defined	No
Marchesi 2003	[24]	2000-2002	Italy	HS	harmonic scalpel	CH	UN	Not clearly defined	No
Ortega 2004	[25]	2001-2002	Spain	HS	UltraCision CS-14C	CH	SS (2 surgeons)	Not clearly defined	No
Cordon 2005	[26]	2001-2002	Mexico	HS	UltraCision shears	CH	SS (1 surgeon)	Operation time	No
Frazzetta 2005	[27]	2003-2004	Italy	SH	UltraCision scalpel	CH	SS (1 surgeon)	Not clearly defined	No
Miccoli 2006	[28]	Unclear	Italy	HS	UltraCision CS-14C	CH	SS (2 surgeons)	Operation time	No
Kilic 2007	[29]	2005	Turkey	SH	UltraCision	CH	UN	Safety and efficacy	No
Hallgrimsson 2008	[30]	2003-2006	Sweden	HS	UltraCision 5.5 mm scalpel	CH	SS+JS (3 senior +	Operation time	Yes
Koh 2008	[31]	2006-2007	Korea	SH	US-140	СН	1 junior surgeon)	Safety and efficacy	No
Vildinim 2000	[30]	2000 2000	Turbour	SII				Not alcould defined	No
1 numun 2008 I ambardi 2008	[77]		Italy	SH	UltraCision CC-14C shaare	CII	SC+ IS (trained and inevnent)	Not clearly defined	
Witted 2000	[75]	0002-1002	Gommony	SII	UIUAUSIOII COTITO SIIVAIS	CII	SS (1 modelist mussion)	Not alcount defined	
W11261 2009	[CC]	0007-0007	Germany	CH	HFU04 Scalper	CII	So (1 specialist surgeon)	not clearly defined	001
Papavramidis 2009	[36]	2008	Greece	SH	UltraCision scalpel	CH	SS (a surgical team dedicated	Not clearly defined	No
Miccoli 2010	[37]	2007-2008	Italy	SH	Focus shears	CH	SS (2 surgeons)	Safety and efficacy	Yes
Mourad 2011	[38]	2008	Belgium	SH	Focus shears	CH	SS (1 surgeon)	Operation time	Yes
Gentileschi 2011	[39]	2010	Italy	SH	Focus	CH	SS (1 experienced surgeon)	Operation time, safety	No
He 2011	[40]	2010	China	SH	Focus	CH	SS (6 adept surgeons)	Operation time, drainage	No
Ferri 2011	[41]	2010-2011	Italy	SH	Focus UlltraCision scalnel	CH	SS (exnerienced survical team)	volume, complications Oneration time nost-onerative	No
	Ξ		611111		indiana molecionario enon i		avpointing anglen count	pain. drainage volume	
Kowalski 2012	[42]	2007–2008	Brazil	HS	scalpel	CH	SS+JS (experienced or pre-trained surgeons)	Combined complications: temp. RLN injury+temp.	Yes
Docimo 2012	[43]	2008-2010	Italy	HS	ultrasonic scalpel	CH	UN	hypocalcaemia Not clearly defined	No
Sista 2012	[44]	2008–2011	Italy	SH	Focus	CH	SS (2 surgeons)	Not clearly defined	No
LS vs. conventional									
Manouras 2005	[45]	2003–2004	Greece	LS	LigaSure Precise	CH	SS (1 surgical team)	Operation time	No
Goretzki 2005	[46, 47]	Unclear	Germany	LS	LigaSure	CH	UN	Not clearly defined	No
Saint Marc 2007	[48]	2004	France	LS	LigaSure	CH	SS (3 experienced surgeons)	Operation time	Yes
Marrazzo 2007	[49]	2004–2005	Italy	LS	LigaSure	CH	UN	Postoperative morbidity	No
Minner 2007	[50]	2004-2005	Germany	LS	Precise	CH	SS+JS (trained+inexpert	Operation time	No
Singh 2010	[51]	Unclear	Canada	LS	LigaSure	CH	surgeons) SS (1 surgeon)	Operation time	Yes

Study	Ref.	Recruitment	Country	Intervention	Instrument	Control	Surgical experience	Primary endpoint	Power analysis
Schiphorst 2012 HS vs. LS (vs. CH)	[52]	2005–2008	NL	LS	LigaSure Precise	СН	SS+JS (1 senior+1 resident)	Operation time	Yes
Sartori 2008	[53]	2007	Italy	HSvs. LS	UltraCision scalpelLigaSure	CH	SS (1 surgical team)	Not clearly defined	No
Pons 2009	[54]	2007-2008	France	HSvs. LS	Focus scalpelAtlas LS1020	CH	UN	Operation time	No
Di Renzo 2010	[55]	2009	Italy	HSvs. LS	Focus shears	CH	SS (1 surgical team)	Not clearly defined	No
Rahbari 2011	[56]	2007–2009	USA	HS	Focus	LS (Precise LS1200)	SS (4 surgeons performed both interventions)	Operation time and cost	Yes
Dionigi 2012	[57]	Unclear	Italy	HS	Focus shears	LS LF1212	SS (2 senior surgeons)	Hypocalcaemia (by iPTH difference)	Yes
Dionigi 2012a	[58]	Unclear	Italy	SH	Focus shears	LS	SS (1 surgical team)	Hypocalcaemia (by iPTH difference)	Yes
CH conventional he	mostasis,	HS harmonic s	calpel, LS I	JigaSure, SS se	nior surgeons, JS junior surge	ons, UN unclear, RLN r	ecurrent laryngeal nerve		

 Table 2 (continued)

operation time than investigator-initiated trials (16.8 vs. 41.9 min, P < 0.001 for subgroup differences, Fig. 5).

When the primary outcome was analysed in subgroups of low, high or unclear risk of imbalances in surgical experience, no differences were detected (P=0.400 for subgroup differences, Fig. 6); the use of HS led to shorter operation times in all subgroups.

Comparison of CH with LS

There were 882 patients in the intervention groups comparing CH with LS. The meta-analysis provided a significant reduction in operation time by 13.0 min (95 % CI, [6.3, 19.7]; P < 0.001; 10 trials, $I^2 = 87$ %; Fig. 7). The mean difference between the CH and LS groups ranged from -11.0 min to + 32.4 min in individual studies.

In the subgroup for total thyroidectomies, five included studies contributed to a computed mean difference of 16.4 min (95 % CI, [7.1, 25.6]; P < 0.001; 5 trials, $I^2 = 91$ %). Subgroup analysis for partial thyroidectomies was not possible as the subgroup was composed of only one study [52]. Our analysis of their data showed a significant reduction of operation time by 15.0 min (95 % CI, [8.3, 21.7]; Fig. 7). Interestingly, in the remaining studies, in which partial and total thyroidectomies are not differentiated, the result calculated for operation time was below 10 min and not statistically significant.

A sensitivity analysis excluding three-arm studies did not substantially affect the results. The sponsor was unclear in the majority of trials for this outcome (7/10), so that no subgroup analysis could be performed by sponsor. The saving of operation time by using LS was significantly lower in trials with a low risk of unbalanced surgical experience than in the others (low risk, 5.4 [0.200, 10.6], 6 trials, I^2 =65 %; high risk, 15.000 [8.3, 21.7], 1 trial; unclear risk, 30.2 [24.0, 36.3], 3 trials, I^2 =0 %; P<0.001 for subgroup differences; Fig. 8). However, because only a single study with high risk of bias due to surgical experience was included, the validity of this result remains unclear.

Comparison of HS with LS

The comparison of HS with LS comprised 673 patients in the relevant intervention groups.

The meta-analysis provided a reduction in operation time by 9.3 min when using HS (95 % CI, [-17.8, -0.8]; P=0.032; 6 studies, $I^2=91$ %; Fig. 9).

A sensitivity analysis was performed excluding the Dionigi trial [57], which was the only study employing the new Ligasure instrument LF1212. When this major source of clinical heterogeneity was removed, both the overall result and the "total thyroidectomy" subgroup results were statistically significant: For total thyroidectomies, the use of the LS was slower by 7.1 min than of the HS (95 % CI, [-11.1, -3.0]; P < 0.001; 2 studies, $I^2 = 0$ %), and overall, the LS led to an

Table 3Baseline characteristicsof included patients

Study	Patients, n	Mean age, years	Women, %	Type of disease	Type of surgery
HS vs. conventional					
Voutilainen 2000 [20]	19 vs. 17	40	94	B and M	Total and partial
Meurisse 2000 [21-23]	17 vs. 17	50	82	В	Total
Marchesi 2003 [24]	72 vs. 70	n.a.	n.a.	В	Total
Ortega 2004 [25]	100 vs. 100	53	83	В	Total and partial
Cordon 2005 [26]	30 vs. 30	n.a.	n.a.	B and M	Total and partial
Frazzetta 2005 [27]	60 vs. 60	54	69	В	Total
Miccoli 2006 [28]	50 vs. 50	46	78	B and M	Total
Kilic 2007 [29]	40 vs. 40	40	86	B and M	Total and partial
Hallgrimsson 2008 [30]	27 vs. 24	40^{a}	76	В	Total
Koh 2008 [31]	31 vs. 34	48	92	М	Total and CND
Yildirim 2008 [32]	50 vs. 54	45	n.a.	В	Total
Lombardi 2008 [33, 34]	100 vs. 100	51	77	B and M	Total
Witzel 2009 [35]	54 vs. 42	54	59	В	Total and partial
Papavramidis 2009 [36]	45 vs. 45	49	86	B and M	Total
Miccoli 2010 [37]	31 vs. 31	51	73	В	Total
Mourad 2011 [38]	34 vs. 34	49	76	B and M	Total
Gentileschi 2011 [39]	43 vs. 38	49	84	B and M	Total
He 2011 [40]	51 vs. 54	47	88	М	Total and lymph nodes
Ferri 2011 [41]	50 vs. 50	50	59	B and M	Total
Kowalski 2012 [42]	128 vs. 133	48	92	B and M	Total and CND
Docimo 2012 [43]	100 vs. 100	46	65	B and M	Total
Sista 2012 [44]	130 vs. 131	50	77	B and M	Total and partial
LS vs. conventional					
Manouras 2005 [45]	94 vs. 90	53	84	B and M	Total
Goretzki 2005 [46, 47]	39 vs. 39	53	88	В	Total and partial
Saint Marc 2007 [48]	100 vs. 100	52	82	В	Total
Marrazzo 2007 [49]	25 vs. 25	52	78	B and M	Total
Minner 2007 [50]	77 vs. 73	53	75	В	Total and partial
Singh 2010 [51]	14 vs. 14	52	71	B and M	Total and partial
Schiphorst 2012 [52]	20 vs. 20	47	88	B and M	Partial
HS vs. LS (vs. CH)					
Sartori 2008 [53]	50 vs. 50 vs. 50	56	85	B and M	Total
Pons 2009 [54]	20 vs. 20 vs. 20	55	80	В	Total
Di Renzo 2010 [55]	31 vs. 31 vs. 31	51	74	В	Total
Rahbari 2011 [56]	45 vs. 45	47	80	B and M	Total and partial+CND
Dionigi 2012 [57]	92 vs. 90	41	80	В	Total
Dionigi 2012a [58]	96 vs. 103	49 ^a	80	В	Total and partial

harmonic scalpel, *LS* LigaSure, *CND* central neck dissection, *B* benign disease, *M* malignant disease, *n.a.* not available ^a Converted from median by the

CH conventional hemostasis, HS

method of Hozo et al. [19]

operation time reduction by 12.3 min [-20.4, -4.2]; P=0.003; 5 studies, $I^2=82$ %). A sensitivity analysis excluding threearm studies was not possible due to the low remaining number of trials, nor was a subgroup analysis for surgical experience because 5/6 trials were performed by experienced surgeons.

Several pooled results for the pairwise comparisons of the primary outcome have to be used with caution because their statistical heterogeneity is really high (maximum 91 %). Nevertheless, there is no change in the direction of the treatment effects for the comparison of CH versus HS (Fig. 4); for only two out of

ten trials, there is a change in direction for the comparison CH versus LS (Fig. 7), and for only one out of six trials, there is a change in direction for the comparison HS versus LS (Fig. 9).

Publication bias

Electronic supplementary material Figures 2, 3 and 4 present the corresponding contour-enhanced funnel plots plotting the WMD against the precision of the study (standard error of the WMD) for pairwise meta-analysis. The shaded areas in the





funnel plots indicate different levels of statistical significance (<0.01, <0.05, <0.1) as an aid to differentiating asymmetry due to publication bias from that due to other bias factors. Only for the comparison conventional techniques versus Harmonic scalpel the Egger's test revealed significant asymmetry, stipulating a significance level of 10 % (CH vs. HS, P=0.055; CH versus LS, P=0.308; HS vs. LS, number of trials too small to test for small study effects). No non-significant trials can be found in the area without shading in the contour-enhanced funnel plot, and therefore, it can be assumed that the asymmetry is caused by publication bias based on statistical significance. The trim-and-fill method revealed pooled weighted mean differences without contradicting the above given results (CH vs. HS, MD 18.0 with 95 % CI 13.8 to 22.5; CH vs. HS, MD 9.1 with 95 % CI 2.3 to 15.8; HS vs. LS, no trim-and-fill method available).

Secondary Endpoints

The pairwise meta-analytical results for all secondary endpoints are presented in Table 5 (CH vs. HS), (CH vs. LS) and (HS vs. LS).

Mortality

No deaths were reported in any included RCT.

Intraoperative blood loss

The mean intraoperative blood loss was generally measured by weighing the gauzes [21, 26, 27, 30, 32, 38], by measuring



Fig. 3 Evidence network for primary endpoint 'operation time'. CH=conventional hemostasis, HS=harmonic scalpel, LS =LigaSure

the fluids collected intra-operatively via suction (Pons 2009), or by a combination of both [53]. The method used was not defined in Voutilainen 2000.

Mean intraoperative blood loss ranged from 21 to 268 mL throughout studies. The pooled value was lower by 28.5 mL for HS compared with CH (P < 0.001) but not significant for LS compared with CH (P=0.520) and HS compared with LS (P=0.448). In a sensitivity analysis comparing HS to CH and excluding three-arm studies (Pons 2009, Sartori 2008), the magnitude of the effect was slightly larger (34.9 mL; 95 % CI [17.4, 52.3]; P < 0.001; I^2 =84 %).

Statistical heterogeneity was high for all three comparisons.

Weight of specimen

Wherever possible, the weights of the thyroid tissue surgically removed was recorded and analysed in order to assess any bias arising in the respective treatment groups. The weighted mean of specimens amounted to 56 g throughout published reports. There were no differences between the intervention groups

Table 4 Primary outcome: operation time [in minutes]

	Network (consiste	c meta-a ency mc	nalysis odel)	Network (inconsi	t meta-a stency r	analysis nodel)
	Mean/ median	SD	CrI	Mean/ median	SD	CrI
d _{CHvsHS}	22.26	1.216	(19.87, 24.65)	22.7	1.262	(20.23, 25.17)
$d_{\rm CHvsLS}$	13.84	1.813	(10.27, 17.39)	12.18	2.110	(8.029, 16.32)
$d_{\rm HSvsLS}$	-8.42	1.889	(-12.14, -4.73)	-2.45	3.593	(-9.484, 4.595)
au	4.91	0.115	(4.573, 4.997)	4.87	0.123	(4.549, 4.997)
resdev	103.4			103.0		
DIC	471.0			471.0		

Posterior summaries from random effects consistency and inconsistency models

SD Mean, standard deviation, CrI 95 % credible interval of absolute treatment effects, τ median of between-trial standard deviation, resdev posterior mean of the total residual deviance, DIC deviance information criterion

1047

		СН			HS			Mean Difference		Mean Di	fference	
Study or Subaroup	Mean [min]	SD [min]	Total	Mean [min]	SD [min]	Total	Weight	IV. Random, 95% CI [min]	Year	IV. Random.	95% CI [min]	
1.1.1 Total Thyroidect	tomy (+ CND)							, , . .				
Meurisse 2000	96.5	28.9	17	70.7	18.3	17	2.7%	25.80 [9.54, 42.06]	2000			
Ortega 2004	101	16	57	86	20	57	4.3%	15.00 [8.35, 21.65]	2004		-	
Frazzetta 2005	97	17	60	56	18	60	4.3%	41.00 [34.74, 47.26]	2005			
Cordon 2005	136	37	12	104	29	7	1.3%	32.00 [2.00, 62.00]	2005		<u> </u>	
Miccoli 2006	46.7	10.8	50	40	6.8	50	4.7%	6.70 [3.16, 10.24]	2006		-	
Lombardi 2008	72.5	23.5	100	53.1	20.7	100	4.3%	19.40 [13.26, 25.54]	2008			
Yildirim 2008	105	16	54	77.9	12.5	50	4.4%	27.10 [21.60, 32.60]	2008		-	
Koh 2008	141.12	22.26	34	98	14.85	31	3.9%	43.12 [33.99, 52.25]	2008			
Hallgrimsson 2008	169.5	50.5	24	134.75	32.25	27	1.8%	34.75 [11.17, 58.33]	2008			
Pons 2009	151	15	20	114	9	20	4.1%	37.00 [29.33, 44.67]	2009			
Papavramidis 2010	101.74	20.76	45	76.67	22.88	45	3.9%	25.07 [16.04, 34.10]	2010			
Miccoli 2010	47.2	14.25	31	33.4	8.5	31	4.4%	13.80 [7.96, 19.64]	2010		-	
Di Renzo 2010	72.7	13.6	31	62.7	14.1	31	4.2%	10.00 [3.10, 16.90]	2010			
Gentileschi 2011	119	30	38	100	34	43	3.1%	19.00 [5.06, 32.94]	2011			
Mourad 2011	80	12	34	57	13	34	4.4%	23.00 [17.05, 28.95]	2011			
Ferri 2011	69.5	10.7	50	44.9	8.3	50	4.6%	24.60 [20.85, 28.35]	2011		-	
He 2011	150.1	32.9	54	102.8	15.6	51	3.8%	47.30 [37.54, 57.06]	2011			
Kowalski 2012	87.8	40.3	133	72.6	33.9	128	3.9%	15.20 [6.18, 24.22]	2012			
Docimo 2012	85	15	100	63	9	100	4.7%	22.00 [18.57, 25.43]	2012		-	
Sista 2012	121	42	122	91	37	119	3.7%	30.00 [20.01, 39.99]	2012			
Subtotal (95% CI)			1066			1051	76.5%	24.87 [19.90, 29.85]			•	
Heterogeneity: Tau ² = Test for overall effect: 2	104.94; Chi² = Z = 9.80 (P < 0	204.28, df).00001)	= 19 (F	² < 0.00001); I	² = 91%							
1.1.2 Partial or Total T	hyroidectom	у										
Voutilainen 2000	134.9	49.4	15	99.1	26.7	18	1.4%	35.80 [7.92, 63.68]	2000			
Kilic 2007	57.8	12	40	47.1	8.2	40	4.6%	10.70 [6.20, 15.20]	2007		-	
Sartori 2008	118	28	50	94	24	50	3.7%	24.00 [13.78, 34.22]	2008		_ <u>_</u> _	
Witzel 2009	95.5	27.5	42	76.3	18.3	54	3.8%	19.20 [9.56, 28.84]	2009		-	
Subtotal (95% CI)			147			162	13.5%	18.61 [9.84, 27.37]			•	
Heterogeneity: Tau ² = 4	47.82; Chi ² = 9	9.19, df = 3	(P = 0.	03); l ² = 67%								
Test for overall effect: 2	Z = 4.16 (P < 0	0.0001)										
1.1.3 Partial Thyroide	ctomy											
Ortega 2004	78	10	43	61	6	43	4.7%	17.00 [13.51, 20.49]	2004		+	
Cordon 2005	112	18	18	93	21	23	3.4%	19.00 [7.05, 30.95]	2005			
Sista 2012	99	27	9	70	21	11	2.0%	29.00 [7.43, 50.57]	2012			
Subtotal (95% CI)			70			77	10.1%	17.44 [14.13, 20.74]			♦	
Heterogeneity: Tau ² =	0.00; Chi ² = 1.	23, df = 2 (P = 0.5	4); l ² = 0%								
Test for overall effect: 2	Z = 10.33 (P <	0.00001)										
Total (95% CI)			1283			1290	100.0%	23.58 [19.59, 27.58]			•	
Heterogeneity: $Tau^2 = 3$	85.93: Chi ² = 2	230.55. df =	= 26 (P	< 0.00001): l ²	= 89%				⊢			
Test for overall effect: 2	Z = 11.56 (P <	0.00001)	(,	,,.					-100	-50	0 50	100
Test for subgroup diffe	rences: Chi² =	6.01, df = 2	2 (P = 0	0.05), l ² = 66.7	%					Favours CH	Favours HS	

Fig. 4 Meta-analysis for the primary outcome 'operation time'; RCTs directly comparing conventional hemostasis (CH) to harmonic scalpel (HS) in thyroidectomies

(P=0.754 for CH vs. HS in 9 studies, 0.566 for CH vs. LS in 2 studies and no data available for HS vs. LS).

Length of hospital stay

The weighted average for the length of hospital stay was 2.7 days for conventional hemostasis procedures. It was lower by 0.28 days for the HS compared with the CH group and did not vary within the other two comparisons. There was a high degree of heterogeneity in this outcome. When three-arm studies were excluded, the result did not change.

Transitory and definitive recurrent laryngeal nerve palsy

Transitory and definitive recurrent laryngeal nerve palsy were common complications, with incidences throughout the CH groups of 4 in 100 patients (66/1,702) and 1 in 100 patients (8/552), respectively. No difference in risk was observed in

the three intervention groups, and the results were highly homogeneous ($I^2=0$ % for each comparison).

Transient and persistent hypocalcaemia

A variety of definitions of postoperative hypocalcaemia are in use [61], and the lack of standardisation will introduce bias for this endpoint. Examples for definitions of postoperative hypocalcaemia in the publications include "numbness in the lips and hands, Chvostek or Trousseau sign, carpopedal spasm", "ionized calcium <8.2 mg/dL [or 1.14 mmol/L], associated with a positive Chvostek sign or patient complaint of paresthesia", or "need for calcium substitution"). In many papers, postoperative hypocalcaemia was not clearly defined. We pooled results only for trials reporting clinically symptomatic, rather than biochemical hypocalcaemia.

Transient hypocalcaemia was very common, with close to two in ten patients affected (272/1,560, 17.4 %). However, only about a tenth of these led to persistent hypocalcaemia

		СН			HS			Mean Difference		Mean Difference
Study or Subaroup	Mean [min]	SD [min]	Total	Mean [min]	SD [min]	Total	Weight	IV. Random, 95% CI [min]	Year	IV. Random, 95% CI [min]
1.17.1 Industry-spons	ored trial	0 - []			[]					
Voutilainen 2000	134.9	49.4	15	99.1	26.7	18	14%	35 80 [7 92 63 68]	2000	
Cordon 2005	112	18	18	93	21	23	3.4%	19.00 [7.05, 30.95]	2005	
Cordon 2005	136	37	12	104	29	7	1.3%	32.00 [2.00, 62.00]	2005	
Miccoli 2006	46.7	10.8	50	40	6.8	50	4.7%	6.70 [3.16, 10.24]	2006	+
Lombardi 2008	72.5	23.5	100	53.1	20.7	100	4.3%	19.40 [13.26, 25.54]	2008	-
Kowalski 2012	87.8	40.3	133	72.6	33.9	128	3.9%	15.20 [6.18, 24.22]	2012	
Subtotal (95% CI)			328			326	19.0%	16.76 [8.96, 24.56]		•
Heterogeneity: Tau ² = Test for overall effect: 2	55.90; Chi² = 2 Z = 4.21 (P < 0	20.29, df = 5 0.0001)	5 (P = 0	0.001); l ² = 75°	%					
1.17.2 Investigator-ini	tiated trial									
Koh 2008	141.12	22.26	34	98	14.85	31	3.9%	43.12 [33.99, 52.25]	2008	
Pons 2009	151	15	20	114	9	20	4.1%	37.00 [29.33, 44.67]	2009	
He 2011	150.1	32.9	54	102.8	15.6	51	3.8%	47.30 [37.54, 57.06]	2011	
Subtotal (95% CI)			108			102	11.7%	41.86 [35.86, 47.86]		•
Heterogeneity: Tau ² = 2 Test for overall effect: 2	8.08; Chi² = 2. Z = 13.68 (P <	.80, df = 2 (: 0.00001)	P = 0.2	5); l² = 29%						
1.17.3 Unclear sponse	or									
Meurisse 2000	96.5	28.9	17	70.7	18.3	17	2.7%	25.80 [9.54, 42.06]	2000	
Ortega 2004	78	10	43	61	6	43	4.7%	17.00 [13.51, 20.49]	2004	-
Ortega 2004	101	16	57	86	20	57	4.3%	15.00 [8.35, 21.65]	2004	
Frazzetta 2005	97	17	60	56	18	60	4.3%	41.00 [34.74, 47.26]	2005	-
Kilic 2007	57.8	12	40	47.1	8.2	40	4.6%	10.70 [6.20, 15.20]	2007	-
Sartori 2008	118	28	50	94	24	50	3.7%	24.00 [13.78, 34.22]	2008	
Hallgrimsson 2008	169.5	50.5	24	134.75	32.25	27	1.8%	34.75 [11.17, 58.33]	2008	
Yildirim 2008	105	16	54	77.9	12.5	50	4.4%	27.10 [21.60, 32.60]	2008	-
Witzel 2009	95.5	27.5	42	76.3	18.3	54	3.8%	19.20 [9.56, 28.84]	2009	
Di Renzo 2010	72.7	13.6	31	62.7	14.1	31	4.2%	10.00 [3.10, 16.90]	2010	-
Miccoli 2010	47.2	14.25	31	33.4	8.5	31	4.4%	13.80 [7.96, 19.64]	2010	-
Papavramidis 2010	101.74	20.76	45	76.67	22.88	45	3.9%	25.07 [16.04, 34.10]	2010	
Gentileschi 2011	119	30	38	100	34	43	3.1%	19.00 [5.06, 32.94]	2011	
Mourad 2011	80	12	34	57	13	34	4.4%	23.00 [17.05, 28.95]	2011	
Ferri 2011	69.5	10.7	50	44.9	8.3	50	4.6%	24.60 [20.85, 28.35]	2011	<u> </u>
Sista 2012	121	42	122	91	37	119	3.7%	30.00 [20.01, 39.99]	2012	
Docimo 2012	85	15	100	63	9	100	4.7%	22.00 [18.57, 25.43]	2012	
Sista 2012 Subtotal (95% CI)	99	27	847	70	21	862	2.0% 69.2%	29.00 [7.43, 50.57] 21.86 [18.09, 25.64]	2012	•
Heterogeneity: $Tau^2 = 4$	47.14; Chi ² = 9	98.59, df =	17 (P <	0.00001); l ² =	83%					
Test for overall effect: 2	Z = 11.35 (P <	0.00001)		,,						
Total (95% CI)			1283			1290	100.0%	23,58 [19,59, 27,58]		♦
Heterogeneity: Tau ² = 3	85 93 [.] Chi ² = 3	230.55 df =	26 (P	< 0.00001). 12	= 89%		/0		⊢	i
Test for overall effect: 2	Z = 11.56 (P <	: 0.00001)	-0 (5070				-100	-50 0 50 100
Test for subgroup diffe	rences: Chi² =	: 36.86, df́ =	2 (P <	0.00001), l ² =	94.6%					Favours CH Favours HS

Fig. 5 Sensitivity analysis for the primary outcome 'operation time' by sponsor (CH vs. HS)

(14/552, 2.5 %). The meta-analytical data point to a marginally higher risk of transient hypocalcaemia with CH compared with HS (RD 0.04; 95 % CI [-0.00, 0.07]; P=0.066; 24 studies, $I^2=62$ %). In a sensitivity analysis excluding threearm studies, this result became statistically significant (RD 0.05; 95 % CI [0.01, 0.09]; P=0.025; 21 studies, $I^2=61$ %).

Still, the combined data from five studies with serum calcium measurements detected no difference for CH compared with HS (WMD -0.004 mmol/L).

No differences in the rate of persistent hypocalcaemia were detectable.

Postoperative bleeding

The amount of postoperative bleeding as defined by the volume of fluids in the suction drainages after 24 h was significantly higher for CH compared with HS by 11.2 mL (endpoint reported in 15 studies; no major difference when excluding three-arm studies), whereas no differences were observed in the other comparisons. However, this did not translate to an increased need for re-operation due to bleeding for this comparison (RD 0.001; 95 % CI [-0.01, 0.01]; nine studies).

Hematoma/seroma

Hematoma and seroma were relatively common, with 4 in 100 patients in the CH groups affected (40/1013 patients, 3.9 %) and balanced throughout intervention groups.

Re-operation

About 1 in 100 patients in the combined CH groups required reoperation (10/1167, 0.9%), in many cases due to post-operative bleeding. Again, the risk did not differ among treatment groups.

Wound infection

Wound infection was an uncommon complication (1/746 CH patients, 0.13 %), and no differences were observed for the three hemostasis methods.

	c	ж			HS			Mean Difference	Mean Difference
Study or Subaroup	Mean [min]	SD [min]	Total	Mean [min]	SD [min]	Total	Weight	IV. Random, 95% CI [min]	IV. Random. 95% CI [min]
1.18.1 Balanced surg	ical experience	9					J	, , 	
Cordon 2005	136	37	12	104	29	7	1.3%	32.00 [2.00, 62.00]	
Cordon 2005	112	18	18	93	21	23	3.4%	19.00 [7.05, 30.95]	
Di Renzo 2010	72.7	13.6	31	62.7	14.1	31	4.2%	10.00 [3.10, 16.90]	
Ferri 2011	69.5	10.7	50	44.9	8.3	50	4.6%	24.60 [20.85, 28.35]	-
Frazzetta 2005	97	17	60	56	18	60	4.3%	41.00 [34.74, 47.26]	-
Gentileschi 2011	119	30	38	100	34	43	3.1%	19.00 [5.06, 32.94]	
He 2011	150.1	32.9	54	102.8	15.6	51	3.8%	47.30 [37.54, 57.06]	
Koh 2008	141.12	22.26	34	98	14.85	31	3.9%	43.12 [33.99, 52.25]	
Miccoli 2006	46.7	10.8	50	40	6.8	50	4.7%	6.70 [3.16, 10.24]	-
Miccoli 2010	47.2	14.25	31	33.4	8.5	31	4.4%	13.80 [7.96, 19.64]	-
Mourad 2011	80	12	34	57	13	34	4.4%	23.00 [17.05, 28.95]	
Ortega 2004	101	16	57	86	20	57	4.3%	15.00 [8.35, 21.65]	-
Ortega 2004	78	10	43	61	6	43	4.7%	17.00 [13.51, 20.49]	-
Papavramidis 2010	101.74	20.76	45	76.67	22.88	45	3.9%	25.07 [16.04, 34.10]	
Sartori 2008	118	28	50	94	24	50	3.7%	24.00 [13.78, 34.22]	
Sista 2012	121	42	122	91	37	119	3.7%	30.00 [20.01, 39.99]	
Sista 2012	99	27	9	70	21	11	2.0%	29.00 [7.43, 50.57]	
Voutilainen 2000	134.9	49.4	15	99.1	26.7	18	1.4%	35.80 [7.92, 63.68]	
Witzel 2009	95.5	27.5	42	76.3	18.3	54	3.8%	19.20 [9.56, 28.84]	
Subtotal (95% CI)			795			808	69.5%	24.01 [18.69, 29.34]	•
Heterogeneity: $1 au^2 =$ Test for overall effect: 2	110.76; Chi² = ⁻ Z = 8.84 (P < 0.	184.51, df : .00001)	= 18 (P	< 0.00001); F	² = 90%				
1 18 2 High risk for u	nhalanced sur	nical evne	rience						
Hallarimsoon 2009	160 5	50 5	24	194 75	20.05	27	1 00/	24 75 [11 17 59 22]	
Kowalski 2012	87.8	40.3	133	726	32.20	128	3.0%	15 20 [6 18 24 22]	
Lombardi 2008	72.5	23.5	100	53.1	20.7	100	4 3%	19 40 [13 26 25 54]	-
Subtotal (95% CI)	72.5	20.0	257	50.1	20.7	255	10.0%	18.89 [12.98, 24.80]	•
Heterogeneity: Tau ² =	5 42 [.] Chi ² = 2 4	1 df = 2 (F)	P = 0.30))· l² = 17%					·
Test for overall effect: 2	Z = 6.26 (P < 0.	.00001)	0.0	,,,.					
1 19 2 Upoloar curaio	al oxporionoo								
Desime 0010		15	100	CO	0	100	4 70/	00 00 [10 57 05 40]	_
Docimo 2012	85	15	100	63	9	100	4.7%	22.00 [18.57, 25.43]	
KIIIC 2007	57.8	12	40	47.1	10.0	40	4.0%	10.70 [6.20, 15.20]	
Neurisse 2000	90.5	28.9	17	70.7	18.3	17	2.1%	25.80 [9.54, 42.06]	
Vildirim 2009	105	15	20	77.0	125	20	4.1%	37.00 [29.33, 44.07]	
Subtotal (95% CI)	105	10	231	11.9	12.0	227	20.5%	24 06 [15 65 32 46]	
Heterogeneity: Tau ² –	76 63: Chi2 - 1	2 11 df - /	L0.	00001) 12 - 0	1%	/	20.0 /0	2100 [10:00, 02:10]	•
Test for overall effect: 2	Z = 5.61 (P < 0.	.00001)	r (i < 0	.00001), 1 = 3	71 /0				
Total (95% CI)			1283			1290	100.0%	23.58 [19.59, 27.58]	•
Heterogeneity: Tau ² =	85.93; Chi ² = 23	30.55, df =	26 (P ·	< 0.00001): l ²	= 89%			· · · · · · · · · · · · · · · · · · ·	
Test for overall effect:	Z = 11.56 (P < 0	0.00001)	- (,,,				-100) -50 0 50 100
Test for subgroup diffe	rences: Chi ² = 1	, 1.83, df = 2	2 (P = 0	.40), l ² = 0%					Favours CH Favours HS

Fig. 6 Sensitivity analysis for the primary outcome 'operation time' by surgical experience (CH vs. HS)

Postoperative pain

Overall, six studies comparing CH versus HS assessed 24-h postoperative pain by a ten-point visual analogue scale. Because of the clinical heterogeneity of these studies, particularly the diversity of pain medication given, as well as the relative mildness of postoperative pain following this type of surgical intervention, the data for this endpoint were not pooled. For the other comparisons, data available were insufficient for pooling.

Cosmetic satisfaction

Cosmetic satisfaction was analysed only by Kilic et al. [29], therefore pooling was not possible. Kilic had explored the patient-reported cosmetic satisfaction on a ten-item visual analogue scale and found a marginally higher cosmetic satisfaction when patients were operated with the HS compared with CH (7.8 \pm 1.1 vs. 7.2 \pm 1.3, P=0.04). However, no patient blinding was reported, and the results might be biased.

Three authors reported the incision length as a cosmetic outcome. The results were not pooled due to their low number. Frazzetta et al. found no difference between CH and HS (5.5 vs. 5.5 cm mean incision length) [27], nor did Lombardi (4.07 ± 0.77 vs. 3.96 ± 0.75 cm) [34]. Dionigi et al. [57] reported the incision length measured with a ruler on the day of discharge. This parameter was lower for the new LF1212 compared with HS (4.4 ± 1.1 vs. 5.4 ± 1.2 cm; P < 0.05) but may be subject to bias because the surgeons performing the incision were not blinded to the haemostatic technique employed [57].

Discussion

This meta-analysis has demonstrated that using energised vessel-sealing systems can significantly reduce operation

		СН		L	S			Mean Difference		Mean Difference
Study or Subgroup	Mean [min]	SD [min]	Total	Mean [min]	SD [min]	Total	Weight	IV, Random, 95% CI [min]	Year	IV, Random, 95% CI [min]
2.1.1 Total Thyroidecton	ny									
Manouras 2005	101.6	34.15	90	87.3	21.33	94	10.8%	14.30 [6.03, 22.57]	2005	
Marrazzo 2007	92.4	27.5	25	60	14.8	25	9.0%	32.40 [20.16, 44.64]	2007	
Saint Marc 2007	48.9	6.8	100	41.5	11.2	100	12.7%	7.40 [4.83, 9.97]	2007	-
Pons 2009	151	15	20	122	10	20	10.9%	29.00 [21.10, 36.90]	2009	
Di Renzo 2010 Subtotal (95% CI)	72.7	13.6	31 266	68.9	7.4	31 270	11.9% 55.2%	3.80 [-1.65, 9.25] 16.36 [7.16, 25.57]	2010	•
Heterogeneity: Tau ² = 95.	.12; Chi ² = 44.	.90, df = 4 (P < 0.0	0001); l ² = 91%	6					
Test for overall effect: Z =	= 3.48 (P = 0.0	0005)								
2.1.2 Partial or Total Thy	roidectomy									
Goretzki 2005	118	36	39	87	34	39	7.6%	31.00 [15.46, 46.54]	2005	
Minner 2007	117.6	36.1	77	107.4	35.2	73	9.3%	10.20 [-1.21, 21.61]	2007	
Sartori 2008	118	28	50	129	32	50	9.2%	-11.00 [-22.79, 0.79]	2008	
Singh 2010	68.5	14.53	14	68.6	27.47	14	7.3%	-0.10 [-16.38, 16.18]	2010	
Subtotal (95% CI)			180			176	33.3%	7.21 [-9.79, 24.21]		•
Heterogeneity: Tau ² = 25 Test for overall effect: Z =	1.24; Chi² = 18 = 0.83 (P = 0.4	8.98, df = 3 1)	(P = 0.	0003); l² = 84%	6					
2.1.3 Partial Thyroidecto	omy									
Schiphorst 2012	69.8	12.8	20	54.8	8.3	20	11.4%	15.00 [8.31, 21.69]	2012	-
Subtotal (95% CI)			20			20	11.4%	15.00 [8.31, 21.69]		•
Heterogeneity: Not applic	able									
Test for overall effect: Z =	= 4.40 (P < 0.0	0001)								
Total (95% CI)			466			466	100.0%	13.00 [6.37, 19.62]		•
Heterogeneity: Tau ² = 88.	.27; Chi ² = 67.	.78, df = 9 (P < 0.0	0001); l ² = 87%	6				⊢	
Test for overall effect: Z =	3.85 (P = 0.0	0001)							-100	-50 0 50 100
Test for subgroup differen	nces: Chi² = 0.	.88, df = 2 (P = 0.6	4), l² = 0%						Favours CH Favours LS

Fig. 7 Meta-analysis for the primary outcome 'operation time'; RCTs directly comparing conventional hemostasis (CH) to LigaSure (LS) in thyroidectomies

time. Additionally, the use of HS was associated with several small-scale benefits, i.e. reduced intra- and postoperative blood loss, reduced rates of transient hypocalcaemia and postoperative pain as well as a reduced duration of hospital stay. While these improvements were marginal and not observed for the use of LS, the conventional technique was not superior in any outcome investigated. In particular, the clinically important safety outcomes of recurrent nerve palsy and rates of clinically symptomatic hypocalcaemia were not negatively affected by using any of the energised vessel

		СН			LS			Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
2.17.1 Balanced surgi	cal exp	erience	•							
Manouras 2005	101.6	34.15	90	87.3	21.33	94	10.8%	14.30 [6.03, 22.57]	2005	
Minner 2007	117.6	36.1	77	107.4	35.2	73	9.3%	10.20 [-1.21, 21.61]	2007	
Saint Marc 2007	48.9	6.8	100	41.5	11.2	100	12.7%	7.40 [4.83, 9.97]	2007	
Sartori 2008	118	28	50	129	32	50	9.2%	-11.00 [-22.79, 0.79]	2008	
Singh 2010	68.5	14.53	14	68.6	27.47	14	7.3%	-0.10 [-16.38, 16.18]	2010	_
Di Renzo 2010	72.7	13.6	31	68.9	7.4	31	11.9%	3.80 [-1.65, 9.25]	2010	+ - -
Subtotal (95% CI)			362			362	61.1%	5.37 [0.20, 10.53]		•
Heterogeneity: Tau ² = 2	22.73; C	hi² = 14	.31, df	= 5 (P =	= 0.01);	$l^2 = 65^{\circ}$	%			
Test for overall effect: 2	Z = 2.04	(P = 0.0)	04)							
2 17 2 High rick for ur	balana	od our		norion						
	IDalaric	eu surg	Jicare	cperien	ce		44.40/	15 00 10 01 01 001	0010	
Schiphorst 2012 Subtotal (95% CI)	69.8	12.8	20 20	54.8	8.3	20 20	11.4% 11.4%	15.00 [8.31, 21.69] 15.00 [8.31, 21.69]	2012	•
Heterogeneity: Not app	licable									
Test for overall effect: 2	Z = 4.40	(P < 0.	0001)							
2.17.3 Unclear surgication	al expe	rience								
Goretzki 2005 118 36 39 87 34 39 7.6% 31.00 [15.46, 46.5								31.00 [15.46, 46.54]	2005	
Marrazzo 2007	92.4	27.5	25	60	14.8	25	9.0%	32.40 [20.16, 44.64]	2007	
Pons 2009	151	15	20	122	10	20	10.9%	29.00 [21.10, 36.90]	2009	
Subtotal (95% CI)			84			84	27.4%	30.15 [24.05, 36.26]		◆
Heterogeneity: Tau ² =	0.00; Ch	$i^2 = 0.2$	2, df = 2	2 (P = 0	.89); l ²	= 0%				
Test for overall effect: 2	Z = 9.68	(P < 0.	00001)							
Total (95% CI)			466			466	100.0%	13.00 [6.37, 19.62]		•
Heterogeneity: Tau ² = 8	88.27; C	hi² = 67	7.78, df	= 9 (P <	< 0.000	D1); l² =	87%		100	
Test for overall effect: 2	Z = 3.85	(P = 0.	0001)						-100	-50 0 50 100
Test for subgroup difference	rences:	Chi ² = 3	6.94, d	lf = 2 (P	< 0.000	001), l ²	= 94.6%			FAVOUIS OF FAVOUIS LS

Fig. 8 Meta-analysis for the primary outcome 'operation time' by surgical experience (CH vs. LS)

	HS			LS			Mean Difference		Mean Difference
Mean [min]	SD [min]	Total	Mean [min]	SD [min]	Total	Weight	IV, Random, 95% CI [min]	Year	IV, Random, 95% CI [min]
tomy									
114	9	20	122	10	20	18.8%	-8.00 [-13.90, -2.10]	2009	
62.7	14.1	31	68.9	7.4	31	19.0%	-6.20 [-11.81, -0.59]	2010	-=-
76	10	92	73	9	90	20.2%	3.00 [0.24, 5.76]	2012	
		143			141	58.0%	-3.39 [-11.10, 4.31]		•
40.22; Chi ² = 1	6.28, df = 2	2 (P = 0	0.0003); l ² = 88	3%					
Z = 0.86 (P = 0).39)								
Thyroidectom	У								
94	24	50	129	32	50	15.3%	-35.00 [-46.09, -23.91]	2008	
184.2	66.2	45	187.6	52.6	45	7.5%	-3.40 [-28.10, 21.30]	2011	
78.5	17	96	87	20	103	19.2%	-8.50 [-13.65, -3.35]	2012	
		191			198	42.0%	-16.70 [-37.05, 3.65]		\bullet
269.22; Chi ² =	18.64, df =	2 (P <	0.0001); l ² = 8	39%					
Z = 1.61 (P = 0).11)								
		334			339	100.0%	-9.31 [-17.80, -0.82]		•
90.68; Chi ² = 5	58.44, df = {	5 (P < 0	0.00001); l ² = 9	91%					
Z = 2.15 (P = 0	0.03)								Favours HS Favours LS
	$\frac{\text{Mean [min]}}{\text{tomy}}$ $\frac{114}{62.7}$ 76 $40.22; Chi^2 = 1$ $Z = 0.86 (P = 0)$ 184.2 78.5 $269.22; Chi^2 = 5$ $Z = 1.61 (P = 0)$ $90.68; Chi^2 = 5$ $Z = 2.15 (P = 0)$	HS <u>Mean [min] SD [min]</u> tomy 114 9 62.7 14.1 76 10 40.22; Chi ² = 16.28, df = 2 Z = 0.86 (P = 0.39) Thyroidectomy 94 24 184.2 66.2 78.5 17 269.22; Chi ² = 18.64, df = Z = 1.61 (P = 0.11) 90.68; Chi ² = 58.44, df = 5 Z = 2.15 (P = 0.03)	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	HS Mean [min] SD [min] Total Mean [min] tomy 114 9 20 122 62.7 14.1 31 68.9 76 10 92 73 40.22; Chi ² = 16.28, df = 2 (P = 0.0003); l ² = 86 2 8 Z = 0.86 (P = 0.39) 143 143 Phyroidectomy 94 24 50 129 184.2 66.2 45 187.6 78.5 17 96 87 191 269.22; Chi ² = 18.64, df = 2 (P < 0.0001); l ² = 8 2 2 = 1.61 (P = 0.11) 334 90.68; Chi ² = 58.44, df = 5 (P < 0.00001); l ² = 8 2 2 = 2.15 (P = 0.03) 12	HS LS Mean [min] SD [min] Total Mean [min] SD [min] tomy 114 9 20 122 10 62.7 14.1 31 68.9 7.4 76 10 92 73 9 40.22; Chi ² = 16.28, df = 2 (P = 0.0003); l ² = 88% Z 88% Z 20.86 (P = 0.39) 143 129 32 184.2 66.2 45 187.6 52.6 78.5 17 96 87 20 191 269.22; Chi ² = 18.64, df = 2 (P < 0.0001); l ² = 89% Z 1.61 (P = 0.11) 334 90.68; Chi ² = 58.44, df = 5 (P < 0.00001); l ² = 91% Z = 2.15 (P = 0.03)	HS LS Mean [min] SD [min] Total Mean [min] SD [min] Total tomy 114 9 20 122 10 20 62.7 14.1 31 68.9 7.4 31 76 10 92 73 9 90 143 141 31 68.9 7.4 31 40.22; Chi ² = 16.28, df = 2 (P = 0.0003); l ² = 88% Z 90 143 141 40.22; Chi ² = 16.28, df = 2 (P = 0.0003); l ² = 88% Z 50 129 32 50 184.2 66.2 45 187.6 52.6 45 78.5 17 96 87 20 103 198 269.22; Chi ² = 18.64, df = 2 (P < 0.0001); l ² = 89% 339 339 339 339 339 339 90.68; Chi ² = 58.44, df = 5 (P < 0.00001); l ² = 91% Z = 2.15 (P = 0.03) 339 339	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	HS LS Mean Difference Mean [min] SD [min] Total Mean [min] SD [min] Total Weight IV, Random, 95% Cl [min] tomy 114 9 20 122 10 20 18.8% 62.7 14.1 31 68.9 7.4 31 19.0% -6.20 [-11.81, -0.59] 76 10 92 73 9 90 20.22% 3.00 [0.24, 5.76] 40.22; Chi ² = 16.28, df = 2 (P = 0.0003); l ² = 88% 141 58.0% -3.39 [-11.10, 4.31] 40.22; Chi ² = 16.28, df = 2 (P = 0.0003); l ² = 88% Z 0.15.3% -35.00 [-46.09, -23.91] 184.2 66.2 45 187.6 52.6 45 7.5% -3.40 [-28.10, 21.30] 78.5 17 96 87 20 103 19.2% -16.70 [-37.05, 3.65] 269.22; Chi ² = 18.64, df = 2 (P < 0.0001); l ² = 89% 339 100.0% -9.31 [-17.80, -0.82] 90.68; Chi ² = 58.44, df = 5 (P < 0.00001); l ² = 91% 339 100.0% -9.31 [-17.80, -0.82] <tr< td=""><td>HS LS Mean Difference Mean [min] SD [min] Total Mean [min] SD [min] Total Weight IV, Random, 95% CI [min] Year tomy 114 9 20 122 10 20 18.8% -8.00 [-13.90, -2.10] 2009 62.7 14.1 31 68.9 7.4 31 19.0% -6.20 [-11.81, -0.59] 2010 76 10 92 73 9 90 20.2% 3.00 [0.24, 5.76] 2012 40.22; Chi² = 16.28, df = 2 (P = 0.0003); l² = 88% 2 32 50 15.3% -35.00 [-46.09, -23.91] 2008 184.2 66.2 45 187.6 52.6 45 7.5% -34.00 [-28.10, 21.30] 2011 78.5 17 96 87 20 103 19.2% -85.00 [-36.5, -3.35] 2012 269.22; Chi² = 18.64, df = 2 (P < 0.0001); l² = 89% 339 100.0% -9.31 [-17.80, -0.82] 90.68; Chi² = 58.44, df = 5 (P < 0.00001); l² = 91% 339 100.0% -9.31 [-17.80, -0.82] 90.68; Chi² = 58</td></tr<>	HS LS Mean Difference Mean [min] SD [min] Total Mean [min] SD [min] Total Weight IV, Random, 95% CI [min] Year tomy 114 9 20 122 10 20 18.8% -8.00 [-13.90, -2.10] 2009 62.7 14.1 31 68.9 7.4 31 19.0% -6.20 [-11.81, -0.59] 2010 76 10 92 73 9 90 20.2% 3.00 [0.24, 5.76] 2012 40.22; Chi² = 16.28, df = 2 (P = 0.0003); l² = 88% 2 32 50 15.3% -35.00 [-46.09, -23.91] 2008 184.2 66.2 45 187.6 52.6 45 7.5% -34.00 [-28.10, 21.30] 2011 78.5 17 96 87 20 103 19.2% -85.00 [-36.5, -3.35] 2012 269.22; Chi² = 18.64, df = 2 (P < 0.0001); l² = 89% 339 100.0% -9.31 [-17.80, -0.82] 90.68; Chi² = 58.44, df = 5 (P < 0.00001); l² = 91% 339 100.0% -9.31 [-17.80, -0.82] 90.68; Chi² = 58

Test for subgroup differences: $Chi^2 = 1.44$, df = 1 (P = 0.23), l² = 30.4%

Fig. 9 Meta-analysis for the primary outcome 'operation time'; RCTs directly comparing harmonic scalpel (HS) to LigaSure (LS) in thyroidectomies

systems. Nevertheless, the detected differences between the devices could be due to the different spectrum of use the devices offer. While the LS offer more time-consuming multiple-sealing approaches at the same vessel, the HS divides the tissue at the same time of coagulation. Harmonic and Ligasure devices have evolved over the years. In particular, the Harmonic has moved from CS 14 to Focus, while the Ligasure Precise now has a blade, which has led to considerable improvement in operating times. Moreover, information on other time-consuming procedures during thyroid surgery, like neuromonitoring, are not entirely included in the analyzed papers.

In contrast to our results, energised vessel sealing systems were described as a potential source of heat-related iatrogenic injury to adjacent structures, especially to the recurrent laryngeal nerve [62]. In our analysis, the percentage of recurrent nerve palsies was low (95%C.I., 3.4–5.7 % for transient recurrence palsies), which is probably partly due to the experience of the surgeons involved in the trials. Recurrence nerve palsies were homogeneously distributed in all three groups. The meta-analysis clearly demonstrates that these energized devices are not a source of RLNs.

Given that complication rates in thyroid surgery are rare, the included trials are underpowered to state a clear benefit in terms of safety of these sealing devices. Thus, future trials within this context should be powered on the basis of existing systematic reviews. Since the clinical relevance of operating time as a primary outcome can be questioned from a patientcentred point of view, upcoming trials should focus on patientreported voice quality apart from nerve and parathyroid vasculature preservations rather than operating time.

Apart from that, reduction of operation time is surely a significant benefit for surgical practice. However, the saving of operation time has to be set in relation to higher material costs. Since personnel and material costs differ from country to country, every single institution has to evaluate the potential benefit of employing these devices.

🖄 Springer

Besides included RCTS our literature search revealed six systematic reviews with meta-analysis investigating haemostatic techniques in thyroid surgery [7–12]. Also, one Cochrane Review protocol (Tam 2010) was found, aiming at investigating hemostasis by using the Ligasure system or harmonic scalpel versus conventional vessel ligation. The protocol was registered on 25 February 2010, but no results have been published yet. However, the literature search in all of these reviews was not comprehensive, and with one exception [10], all investigated only pairwise comparisons. Yao included four randomized and five non-randomized trials; Zhang included one trial in the analysis that was clearly not randomized [63]. A recently published network meta-analysis [13] included all trials published till June 2012. In the analysis performed by Garas, a publication on minimally invasive thyroidectomies [64] was included, and although the inclusion criteria excluded other devices other than the Ligasure, a publication using the Starion[®] vessel sealing system was included [65]. Moreover, the primary endpoints of the metaanalysis are the rate of persistent hypoparathyroidism and rate of persistent recurrence palsies. However, the authors do not stratify the data according to the extent of surgery (partial versus complete thyroidectomy). Thus, a major source of bias is introduced since after a hemithyroidectomy the possibility of persistent hypocalcaemia is very low. Furthermore, other relevant surgical outcomes are not reported (i.e. transient hypocalcaemia and transient recurrence palsy, weight of the specimen, wound-infection rates, reoperation rates, cosmetic result and postoperative pain.

Due to incompleteness of relevant literature and lack of a well-founded interpretation of the results the review's results should be read with caution. However, despite incomplete evidence, the conclusions of most of the reviews are mainly in accordance with our results regarding a significant reduction of operating time in favour of the energized devices over conventional haemostatic techniques for partial and total thyroidectomies.

Table 5Meta-analysis of thesecondary outcome measuresfor RCTs

Outcome	Trials	Participants	Method	Pooled effect, 95 % CI	P value	I^2
CH vs. HS						
Mortality	17	1,411	RD	0.000 [-0.010, 0.010]	1.000	0 %
Intraoperative blood loss [mL]	9	613	MD	28.487 [12.072, 44.902]	< 0.001	91 %
Weight of specimen [g]	9	848	MD	-1.139 [-8.271, 5.992]	0.754	60 %
Length of hospital stay [days]	18	2,032	MD	0.281 [0.052, 0.510]	0.016	90 %
Transitory recurrence palsy	25	2,715	RD	0.001 [-0.010, 0.012]	0.847	0 %
Definitive recurrence palsy	23	2,254	RD	0.002 [-0.007, 0.010]	0.711	0 %
Hypocalcaemia, transient	24	2,625	RD	0.035 [-0.002, 0.072]	0.066	62 %
Hypocalcaemia, persistent	7	846	RD	0.006 [-0.008, 0.021]	0.394	0 %
Serum calcium [mmol/L]	5	334	MD	-0.004 [-0.060, 0.053]	0.904	76 %
Post-operative bleeding [mL]	15	1,721	MD	11.233 [4.822, 17.643]	< 0.001	80 %
Post-operative bleeding (re-OP)	9	1,097	RD	0.001 [-0.012, 0.014]	0.852	0 %
Hematoma/seroma (sum)	16	1,723	RD	0.005 [-0.008, 0.019]	0.425	0 %
Re-operation	13	1,553	RD	0.002 [-0.008, 0.012]	0.723	0 %
Wound infection	11	1,226	RD	-0.004 [-0.014, 0.007]	0.491	0 %
CH vs. LS						
Mortality	6	746	RD	0.000 [-0.011, 0.011]	1.000	0 %
Intraoperative blood loss [mL]	2	140	WMD	7.071 [-14.488, 28.630]	0.520	86 %
Weight of specimen [g]	2	262	WMD	-4.955 [-21.891, 11.981]	0.566	75 %
Length of hospital stay [days]	4	496	WMD	0.071 [-0.104, 0.246]	0.427	57 %
Transitory recurrence palsy	8	670	RD	-0.011 [-0.041, 0.018]	0.459	0 %
Definitive recurrence palsy	6	492	RD	-0.001 [-0.021, 0.018]	0.887	0 %
Hypocalcaemia, transient	6	480	RD	-0.016 [-0.077, 0.046]	0.620	0 %
Hypocalcaemia, persistent	2	262	RD	0.008 [-0.022, 0.037]	0.611	0 %
Post-operative bleeding [mL]	2	90	WMD	0.358 [-7.925, 8.641]	0.932	0 %
Post-operative bleeding (re-OP)	4	258	RD	-0.022 [-0.062, 0.018]	0.286	0 %
Hematoma/seroma (sum)	3	290	RD	-0.004 [-0.039, 0.031]	0.824	7 %
Wound infection	2	262	RD	0.000 [-0.018, 0.018]	1.000	0 %
Re-operation	7	714	RD	-0.007 [-0.025, 0.011]	0.447	0 %
HS vs. LS						
Mortality	2	162	RD	0.000 [-0.032, 0.032]	1.000	0 %
Intraoperative blood loss	2	140	WMD	-6.068 [-21.747, 9.612]	0.448	75 %
Length of hospital stay	4	483	WMD	-0.006 [-0.050, 0.037]	0.783	0 %
Transitory recurrence palsy	5	583	RD	0.001 [-0.029, 0.030]	0.968	0 %
Definitive recurrence palsy	6	673	RD	0.000 [-0.012, 0.012]	1.000	0 %
Hypocalcemia, transient	5	583	RD	0.072 [-0.001, 0.144]	0.052	27 %
Serum calcium concentration	3	481	WMD	0.020 [-0.063, 0.104]	0.629	95 %
Post-operative bleeding [mL]	3	421	WMD	9.937 [-7.472, 27.346]	0.263	89 %
Post-operative bleeding (re-OP)	2	239	RD	0.001 [-0.026, 0.027]	0.962	0 %
Hematoma/seroma (sum)	4	533	RD	0.000 [-0.017, 0.018]	0.982	0 %
Wound infection	3	301	RD	-0.008 [-0.032, 0.016]	0.526	0 %
Re-operation	2	261	RD	0.001 [-0.025, 0.026]	0.964	0 %

n.a. not applicable

Whether surgical experience was equally distributed among groups was not possible to assess in any case. A sensitivity analysis for surgical experience, however, did not show any significant difference. Voutilainen et al. provided an estimate of the amount of bias that could be caused by the differences in surgical experience among the intervention groups [20]. They observed that the gain of the HS could amount to 1.66 times the actual observed gain in the trial if the consultant endocrine surgeon exclusively uses the new method and the senior residents employ the conventional technique alone.

Due to the wide range of included trial participants, covering patients from both male and female genders, with typical age ranges, benign and malign pathologies, partial and total thyroidectomies and geographic locations spread over four continents, the external validity of these findings are expected to be high. Moreover, the included sample size should be adequate to allow generalisability of these results.

Conclusion

This study provides a quantitative three-way comparison of CH with HS and LS in thyroid surgery. The results showed a significant reduction of operation time of HS and LS compared with CH and a marginal benefit of HS for several safety outcomes. The postoperative morbidity is not affected by employing energised devices.

Moreover, the results of our review may be useful for highvolume centres performing many thyroidectomies a day whereas a time saving of 23 min is hardly relevant for institutions with a low operation volume.

Acknowledgements	None
Conflicts of interest	None
Sources of funding	None

References

- Bhattacharyya N, Fried MP (2002) Assessment of the morbidity and complications of total thyroidectomy. Arch Otolaryngol Head Neck Surg 128(4):389–392
- Chiang FY, Lee KW, Huang YF, Wang LF, Kuo WR (2004) Risk of vocal palsy after thyroidectomy with identification of the recurrent laryngeal nerve. Kaohsiung J Med Sci 20(9):431–436
- Lo CY, Kwok KF, Yuen PW (2000) A prospective evaluation of recurrent laryngeal nerve paralysis during thyroidectomy. Arch Surg 135(2):204–207
- Dedivitis RA, Pfuetzenreiter EG Jr, Castro MA, Denardin OV (2009) Analysis of safety of short-stay thyroid surgery. Acta Otorhinolaryngol Ital 29(6):326–330
- Shindo M, Stern A (2010) Total thyroidectomy with and without selective central compartment dissection: a comparison of complication rates. Arch Otolaryngol Head Neck Surg 136(6):584–587. doi: 10.1001/archoto.2010.79
- Slakey DP (2008) Laparoscopic liver resection using a bipolar vesselsealing device: LigaSure. HPB (Oxford) 10(4):253–255. doi:10. 1080/13651820802166880
- Macario A, Dexter F, Sypal J, Cosgriff N, Heniford BT (2008) Operative time and other outcomes of the electrothermal bipolar vessel sealing system (LigaSure) versus other methods for surgical hemostasis: a meta-analysis. Surg Innov 15(4):284–291. doi:10. 1177/1553350608324933
- Yao HS, Wang Q, Wang WJ, Ruan CP (2009) Prospective clinical trials of thyroidectomy with LigaSure vs conventional vessel ligation: a systematic review and meta-analysis. Arch Surg 144(12):1167– 1174. doi:10.1001/archsurg.2009.201
- Cirocchi R, D'Ajello F, Trastulli S, Santoro A, Di Rocco G, Vendettuoli D, Rondelli F, Giannotti D, Sanguinetti A, Minelli L, Redler A, Basoli A, Avenia N (2010) Meta-analysis of thyroidectomy with ultrasonic dissector versus conventional clamp and tie. World J Surg Oncol 8:112. doi:10.1186/1477-7819-8-112

- Ecker T, Carvalho AL, Choe JH, Walosek G, Preuss KJ (2010) Hemostasis in thyroid surgery: harmonic scalpel versus other techniques—a meta-analysis. Otolaryngol Head Neck Surg 143(1):17– 25. doi:10.1016/j.otohns.2010.03.018
- Melck AL, Wiseman SM (2010) Harmonic scalpel compared to conventional hemostasis in thyroid surgery: a meta-analysis of randomized clinical trials. Int J Surg Oncol 2010:396079. doi:10.1155/ 2010/396079
- Zhang ZJ, Zhang P, Tian JH, Li J, Li L, Tian J, Yang KH (2010) Ultrasonic coagulator for thyroidectomy: a systematic review of randomized controlled trials. Surg Innov 17(1):41–47. doi:10.1177/ 1553350610362084
- Garas G, Okabaysashi K, Ashrafian H, Shetty K, Palazzo F, Tolley NS, Darzi A, Athanasiou T, Zacharakis E (2013) Which hemostatic device in thyroid surgery? A network meta-analysis of surgical technologies. Thyroid. doi:10.1089/thy.2012.0588
- Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. doi:10.1136/bmj.b2535
- Higgins JPT (2011) Cochrane handbook for systematic reviews of interventions. Cochrane book series, reprinted edn. Wiley-Blackwell, Chichester, UK
- Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928. doi:10.1136/bmj.d5928
- Cooper NJ, Sutton AJ, Lu G, Khunti K (2006) Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Archives of internal medicine 166(12):1269–1275. doi: 10.1001/archinte.166.12.1269
- Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of clinical epidemiology 50(6): 683–691
- Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology 5:13. doi:10.1186/1471-2288-5-13
- 20. Voutilainen PE, Haglund CH (2000) Ultrasonically activated shears in thyroidectomies: a randomized trial. Ann Surg 231(3):322–328
- Meurisse M, Defechereux T, Maweja S, Degauque C, Vandelaer M, Hamoir E (2000) Evaluation of the Ultracision ultrasonic dissector in thyroid surgery. Prospective randomized study. Ann Chir 125(5): 468–472
- Defechereux T, Rinken F, Maweja S, Hamoir E, Meurisse M (2003) Evaluation of the ultrasonic dissector in thyroid surgery. A prospective randomised study. Acta Chir Belg 103(3):274–277
- Coimbra C, Defechereux T, Meurisse N, Squifflet JP, Meurisse M (2007) [Ultrasonic scalpel in thyroid surgery]. Rev Med Liege 62 Spec No:83–85
- Marchesi M, Biffoni M, Cresti R, Mulas MM, Turriziani V, Berni A, Campana FP (2003) Ultrasonic scalpel in thyroid surgery. Chirurgia italiana 55(2):299–308
- 25. Ortega J, Sala C, Flor B, Lledo S (2004) Efficacy and costeffectiveness of the UltraCision harmonic scalpel in thyroid surgery: an analysis of 200 cases in a randomized trial. J Laparoendosc Adv Surg Tech A 14(1):9–12. doi:10.1089/109264204322862289
- Cordon C, Fajardo R, Ramirez J, Herrera MF (2005) A randomized, prospective, parallel group study comparing the Harmonic Scalpel to electrocautery in thyroidectomy. Surgery 137(3):337–341. doi:10. 1016/j.surg.2004.09.011
- Frazzetta M, Furgiuele G, Raimondo D, Sammartano A, Mannino E, De Simone G, Vetri G, Bonventre S, Di Gesu G (2005) Ultrasonic dissector for total thyroidectomy: results of prospective randomized study. G Chir 26(8–9):295–301
- Miccoli P, Berti P, Dionigi G, D'Agostino J, Orlandini C, Donatini G (2006) Randomized controlled trial of harmonic scalpel use during

thyroidectomy. Arch Otolaryngol Head Neck Surg 132(10):1069–1073. doi:10.1001/archotol.132.10.1069

- Kilic M, Keskek M, Ertan T, Yoldas O, Bilgin A, Koc M (2007) A prospective randomized trial comparing the harmonic scalpel with conventional knot tying in thyroidectomy. Adv Ther 24(3):632–638
- Hallgrimsson P, Loven L, Westerdahl J, Bergenfelz A (2008) Use of the harmonic scalpel versus conventional haemostatic techniques in patients with Grave disease undergoing total thyroidectomy: a prospective randomised controlled trial. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie 393(5):675–680. doi:10. 1007/s00423-008-0361-z
- Koh YW, Park JH, Lee SW, Choi EC (2008) The harmonic scalpel technique without supplementary ligation in total thyroidectomy with central neck dissection: a prospective randomized study. Ann Surg 247(6):945–949. doi:10.1097/SLA.0b013e31816bcd61
- 32. Yildirim O, Umit T, Ebru M, Bulent U, Belma K, Betul B, Mete D, Omer C (2008) Ultrasonic harmonic scalpel in total thyroidectomies. Adv Ther 25(3):260–265. doi:10.1007/s12325-008-0024-z
- 33. Dibidino RRM, Marchetti M, Lombardi N, Raffaelli M, Attina G, Cicchetti A (2010) Harmonic study: a cost-effectiveness evaluation of ultrasonically activated shears for total thyroidectomy. PharmacoEconomics-Italian Research Articles 12(3):143–155
- 34. Lombardi CP, Raffaelli M, Cicchetti A, Marchetti M, De Crea C, Di Bidino R, Oragano L, Bellantone R (2008) The use of "harmonic scalpel" versus "knot tying" for conventional "open" thyroidectomy: results of a prospective randomized study. Langenbeck's Archives of Surgery/Deutsche Gesellschaft fur Chirurgie 393(5):627–631. doi: 10.1007/s00423-008-0380-9
- Witzel K, von Rahden BH, Stein HJ (2009) The effect of ultrasound dissection in thyroid surgery. Eur Surg Res 43(2):241–244. doi:10. 1159/000226257
- Papavramidis TS, Sapalidis K, Michalopoulos N, Triantafillopoulou K, Gkoutzamanis G, Kesisoglou I, Papavramidis ST (2010) UltraCision harmonic scalpel versus clamp-and-tie total thyroidectomy: a clinical trial. Head & neck 32(6):723–727. doi:10.1002/hed. 21240
- Miccoli P, Materazzi G, Miccoli M, Frustaci G, Fosso A, Berti P (2010) Evaluation of a new ultrasonic device in thyroid surgery: comparative randomized study. Am J Surg 199(6):736–740. doi:10. 1016/j.amjsurg.2009.04.003
- Mourad M, Rulli F, Robert A, Scholtes JL, De Meyer M, De Pauw L (2011) Randomized clinical trial on Harmonic Focus shears versus clamp-and-tie technique for total thyroidectomy. Am J Surg 202(2): 168–174. doi:10.1016/j.amjsurg.2010.07.047
- Gentileschi P, D'Ugo S, Iaculli E, Gaspari AL (2011) Harmonic Focus versus "knot tying" during total thyroidectomy: a randomized trial. Updates Surg 63(4):277–281. doi:10.1007/s13304-011-0099-y
- 40. He Q, Zhuang D, Zheng L, Zhou P, Chai J, Lv Z (2011) Harmonic focus in total thyroidectomy plus level III-IV and VI dissection: a prospective randomized study. World J Surg Oncol 9:141. doi:10. 1186/1477-7819-9-141
- Ferri E, Armato E, Spinato G, Spinato R (2011) Focus harmonic scalpel compared to conventional haemostasis in open total thyroidectomy: a prospective randomized trial. Int J Otolaryngol 2011: 357195. doi:10.1155/2011/357195
- 42. Kowalski LP, Sanabria A, Vartanian JG, Lima RA, de Mendonca UB, dos Santos CR, Boldrini D Jr, de Mello LE, Pinto FP, Lehn CN, Correa LA, Dedivitis RA, Guimaraes AV, Pedruzzi PA, Ramos GH, Goncalves AJ, Suehara AB, Kanda JL, Capuzzo Rde C, de Oliveira JC, Curado MP, de Gois Filho JF, Fukuyama E, Beserra IM Jr, de Carvalho Neto PB, Carvalho AL (2012) Total thyroidectomy with ultrasonic scalpel: a multicenter, randomized controlled trial. Head & neck 34(6):805–812. doi:10.1002/hed.21815
- 43. Docimo G, Ruggiero R, Gubitosi A, Casalino G, Bosco A, Gili S, Conzo G, Docimo L (2012) Ultrasound scalpel in thyroidectomy. Prospective randomized study, Ann Ital Chir

- 44. Sista F, Schietroma M, Ruscitti C, De Santis G, De Vita F, Carlei F, Amicucci G (2012) New ultrasonic dissector versus conventional hemo-
- Adv Surg Tech A 22(3):220–224. doi:10.1089/lap.2011.0266
 45. Manouras A, Lagoudianakis EE, Antonakis PT, Filippakis GM, Markogiannakis H, Kekis PB (2005) Electrothermal bipolar vessel sealing system is a safe and time-saving alternative to classic suture ligation in total thyroidectomy. Head & neck 27(11):959–962. doi: 10.1002/hed.20271

stasis in thyroid surgery: a randomized prospective study. J Laparoendosc

- Goretzki PE, Pohl P, Terorde N, Krause-Paulus RM, Lammers BJ (2005) [New methods in thyroid surgery—the ligation free preparation and dissection with LigaSure]. Viszeralchirurgie (3):214–218
- Goretzki PE, Schwarz K, Lammers BJ (2009) Implementing the general use of dissection devices in thyroid surgery from prospective randomized trial to daily use. Surg Technol Int 18:86–92
- Saint Marc O, Cogliandolo A, Piquard A, Fama F, Pidoto RR (2007) LigaSure vs clamp-and-tie technique to achieve hemostasis in total thyroidectomy for benign multinodular goiter: a prospective randomized study. Arch Surg 142(2):150–156. doi:10.1001/archsurg.142.2. 150, discussion 157
- Marrazzo A, Casa L, David M, Lo Gerfo D, Noto A, Riili I, Taormina P (2007) Thyroidectomy with LigaSure versus traditional thyroidectomy: our experience. Chirurgia italiana 59(3):361–365
- Minner S, Rodiger H, Mansmann U, Bohm B (2007) Randomized controlled trial on vessel sealing in thyroid surgery. Zentralbl Chir 132(5):446–450. doi:10.1055/s-2007-981279
- Singh P, O'Connell D, Langille M, Dziegielewski P, Allegretto M, Harris J (2010) LigaSure versus conventional hemostasis in thyroid surgery: prospective randomized controlled trial. J Otolaryngol Head Neck Surg 39(4):378–384
- Schiphorst AH, Twigt BA, Elias SG, van Dalen T (2012) Randomized clinical trial of LigaSure versus conventional suture ligation in thyroid surgery. Head Neck Oncol 4:2. doi:10.1186/1758-3284-4-2
- 53. Sartori PV, De Fina S, Colombo G, Pugliese F, Romano F, Cesana G, Uggeri F (2008) Ligasure versus Ultracision in thyroid surgery: a prospective randomized study. Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie 393(5):655–658. doi:10.1007/ s00423-008-0386-3
- Pons Y, Gauthier J, Ukkola-Pons E, Clement P, Roguet E, Poncet JL, Conessa C (2009) Comparison of LigaSure vessel sealing system, harmonic scalpel, and conventional hemostasis in total thyroidectomy. Otolaryngol Head Neck Surg 141(4):496–501. doi:10.1016/j. otohns.2009.06.745
- 55. Di Renzo RM, Bove A, Bongarzoni G, Palone G, Corradetti L, Corbellini L (2010) Comparison of conventional technique, Ligasure Precise and Harmonic Focus in total thyroidectomy. G Chir 31(6–7):296–298
- Rahbari R, Mathur A, Kitano M, Guerrero M, Shen WT, Duh QY, Clark OH, Kebebew E (2011) Prospective randomized trial of ligasure versus harmonic hemostasis technique in thyroidectomy. Ann Surg Oncol 18(4):1023–1027. doi:10.1245/s10434-010-1251-5
- 57. Dionigi G, Boni L, Rausei S, Frattini F, Ferrari CC, Mangano A, Leotta A, Franchin M (2012) The safety of energy-based devices in open thyroidectomy: a prospective, randomised study comparing the LigaSure (LF1212) and the Harmonic(R) FOCUS. Langenbeck's Archives of Surgery/Deutsche Gesellschaft fur Chirurgie 397(5): 817–823. doi:10.1007/s00423-011-0898-0
- Dionigi G, Van Slycke S, Rausei S, Boni L, Dionigi R (2012) Parathyroid function after open thyroidectomy: a prospective randomized study for ligasure precise versus harmonic FOCUS. Head & neck. doi:10.1002/hed.23005
- 59. Dias S WN, Sutton AJ, Ades AE (2011) NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Clinical Excellence (NICE) http:// www.nicedsu.org.uk. Accessed March 2013

- 60. Dias S WN, Sutton AJ, Caldwell DM, Lu G, Ades AE (2011) NICE DSU Technical Support Document 4: inconsistency in networks of evidence based on randomised controlled trials. National Institute for Health and Clinical Excellence (NICE) http://www.nicedsu.org.uk. Accessed March 2013
- Mehanna HM, Jain A, Randeva H, Watkinson J, Shaha A (2010) Postoperative hypocalcemia—the difference a definition makes. Head & neck 32(3):279–283. doi:10.1002/hed.21175
- 62. Dionigi G (2009) Energy based devices and recurrent laryngeal nerve injury: the need for safer instruments. Langenbeck's Archives of Surgery/Deutsche Gesellschaft fur Chirurgie 394 (3):579–580; author reply 581–576. doi:10.1007/s00423-008-0454-8
- Karvounaris DC, Antonopoulos V, Psarras K, Sakadamis A (2006) Efficacy and safety of ultrasonically activated shears in thyroid surgery. Head & neck 28(11):1028–1031. doi:10.1002/hed.20445
- 64. Barczynski M, Konturek A, Cichon S (2008) Minimally invasive video-assisted thyreoidectomy (MIVAT) with and without use of harmonic scalpel—a randomized study. Langenbeck's Archives of Surgery/Deutsche Gesellschaft fur Chirurgie 393(5):647–654. doi: 10.1007/s00423-008-0373-8
- 65. Scerrino G, Paladino NC, Di Paola V, Morfino G, Matranga D, Gulotta G, Bonventre S (2010) Total thyroidectomy performed with the Starion vessel sealing system versus the conventional technique: a prospective randomized trial. Surg Innov 17(3):242–247. doi:10. 1177/1553350610376394

Authors' contributions

Pietro Contin: Literature search, Data extraction, Risk of bias assessment, Manuscript draft

Käthe Gooßen: Updated literature search, Duplicate data extraction, Risk of bias assessment, Reviewed statistical analysis, Reviewed manuscript

Kathrin Grummich: Updated literature search, Duplicate data extraction, Risk of bias assessment

Katrin Jensen: planned, performed and interpreted the statistical analysis

Hubertus Schmitz-Winnenthal: Helped to draft the manuscript

Markus W. Büchler: Helped to draft the manuscript

Markus K. Diener: Helped to draft the manuscript and helped in the analysis and interpretation of data

PC carried out the search, extracted the data, assisted in the risk of bias assessment and drafted the manuscript. KGo and KGr updated the search, performed the duplicate data extraction and assessed the risk of bias. KGo updated and critically reviewed the statistical analysis and manuscript draft. KJ planned, performed and interpreted the statistical analysis. MD helped to draft the manuscript and helped in the analysis and interpretation of data. HSW and MWB helped to draft the manuscript. All authors read and approved the final manuscript.